MannKind shares rocked on alleged scandel. After the bell: Jazz soars on strong earnings Print E-mail
By BioMedReports.com Staff   
Thursday, 04 November 2010 18:51

Below is a look at some of the headlines for companies that made news in the healthcare sector on November 4, 2010.


Shares of Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ) soared in extended trading today after the company announced financial results for the third quarter ended September 30, 2010, and updated financial guidance for 2010. The company's updated 2010 financial guidance was attributed to higher expected sales of XYREM® (sodium oxybate) oral solution as well as lower anticpated expenses.

In the after hours session, shares of Jazz surged $1.43 or 11.5% to $13.90.

Meanwhile, shares of DexCom, Inc. (Nasdaq:DXCM) were falling after bell. The company reported late Thursday Q3 revenues that fell short of expectations. Shares were down in $1.41 or 10% to $12.50 in extended trading.

Shares of MannKind Corp. (Nasdaq:MNKD) were rocked today after it was reported today that a former employee, John Arditi, is accusing the company of of covering up potential fraud in clinical trials for it's diabetes treatment, Afrezza. Arditi claims he was fired by MannKind after discovering the possible fraud. On volume of 12 million shares, MannKind fell 11% or 68 cents to $5.51 in Thursday trading.

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that is has been awarded approximately $2.0 million in eight federal grants under the Qualifying Therapeutic Discovery Project (QTDP) program.

Antigenics Inc. (Nasdaq:AGEN) today announced that it has been awarded $424,720 in grants under the IRS' Qualifying Therapeutic Discovery Project (QTDP) program. The grants were awarded in recognition of our two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon(R) adjuvant.

Bovie Medical Corporation (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company has applied for 510(k) clearance from the Food and Drug Administration (FDA) to market its J-Plasma handpiece with retractable cutting features in both laparoscopic and open configurations. The newly developed devices will offer soft tissue coagulation and/or tissue cutting with and without simultaneously applied J-Plasma energy.

CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, announced today the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects.

Emergent BioSolutions Inc. (NYSE:EBS) announced today that its fully human anthrax monoclonal antibody AVP-21D9, which is in development for the treatment of inhalation anthrax, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). Orphan status is given to drugs and biologics that are being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in the U.S.

Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

Northwest Biotherapeutics (OTC Bulletin Board:NWBO.ob) today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

NWBT is developing DCVax® personalized immune therapies for treatment of most cancers: a whole new category of cancer treatments (without toxicity). As previously reported, patients treated with DCVax® have shown striking extensions of survival in brain cancer and late stage prostate cancer in clinical trials to date.

Novavax, Inc. (Nasdaq:NVAX) announced today that it has been awarded approximately $978,000 in grants under the Internal Revenue Service's Qualifying Therapeutic Discovery Project.

Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.AdCare Health Systems, Inc. (NYSE Amex:ADK), a recognized innovator in senior living and health care facility management, will hold a conference call on Tuesday, November 16, 2010 at 10:30 a.m. Eastern time to discuss results for the third quarter ended September 30, 2010.

Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN) will be presenting at the Credit Suisse Healthcare Conference in Phoenix, Arizona on Thursday, November 11, 2010 at 5:30 p.m. ET / 2:30 p.m. PT.

Arena Pharmaceuticals, Inc. (Nasdaq:ARNA) today announced it will report third quarter 2010 financial results before the NASDAQ Global Market opens on Tuesday, November 9, 2010.

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) will announce its third quarter 2010 financial and operating results on Tuesday, November 9, 2010.

AspenBio Pharma, Inc. (NASDAQ:APPY) today announced the receipt of a cash grant of approximately $250,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

Atrion Corporation (NASDAQ:ATRI) today announced that for the third quarter of 2010 diluted earnings per share were up 21% and revenues were up 8% compared to the results for the third quarter of 2009.

BioMed Realty Trust, Inc. (NYSE:BMR), a real estate investment trust focused on Providing Real Estate to the Life Science Industry®, today announced financial results for the third quarter ended September 30, 2010.

CardioGenics Holdings Inc. (OTC Bulletin Board:CGNH) announced today that it has completed a private placement under which it has raised $1,930,575.

Cellceutix Corporation (PINKSHEETS: CTIX) today announced that it has been awarded approximately $730,000 in total grants under the Qualifying Therapeutic Discovery Project program.

Chembio Diagnostics, Inc. (OTCBB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported its results for the third quarter of 2010.

Coventry Health Care, Inc. (NYSE: CVH) announced today that Kevin Conlin will join the Company as Executive Vice President.In this capacity, Mr. Conlin will have broad strategic and operational responsibility and help develop innovative products and business partnerships to move the Company forward in the post-health reform environment.His appointment takes effect on January 3, 2011.

Cytori Therapeutics (NASDAQ: CYTX) reports third quarter and nine month 2010 financial results.

Edwards Lifesciences Corporation (NYSE:EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Credit Suisse Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona on Thursday, November 11, 2010.

eHealthInsurance (NASDAQ: EHTH), the leading online source of health insurance for individuals and families, released a ten-point checklist designed to help consumers make smart health insurance decisions during open enrollment season.

eResearchTechnology, Inc. (ERT), (Nasdaq:ERES), a global provider of technology and services to the pharmaceutical, biotechnology, and medical device industries, announced today results for the three and nine months ended September 30, 2010.

Genesis Biopharma, Inc. (OTC Bulletin Board:GNBP), a biotechnology company developing targeted cancer therapies, today announced that the European Patent Office (EPO) has issued EPO Patent Grant No. 1565494 providing broad coverage on Genesis anti-CD55 antibodies for use as a therapeutic treatment in multiple cancers.

Genoptix, Inc. (Nasdaq:GXDX), a specialized laboratory services provider, today reported revenues of $49.5 million for the third quarter of 2010. Net income was $4.4 million or $0.24 per diluted share for the quarter.

GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board:GOVX), an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project ("QTDP") program.

China Green Material Technologies, Inc. (OTC Bulletin Board:CAGM), a Chinese leader in developing and manufacturing starch-based biodegradable and disposable food containers, tableware and packaging materials, today announced that it will release its third quarter 2010 financial results on Wednesday, November 10, 2010 before the market opens.

Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program.

Harte-Hanks (NYSE: HHS), a leading provider of direct and targeted marketing services, announced today that The Agency Inside Harte-Hanks and its client Abbott Laboratories have won a Silver MM&M Award in this year's Medical Marketing & Media (MM&M) Awards, recognizing the top healthcare and pharmaceutical advertising and marketing campaigns.

Impact Fusion International Inc. (PINKSHEETS: IFUS) -- The Company announced today Dr. Bear Walker, the Company's new Medical Advisory Board Chair, will represent the company at the Navel Expo to be held on Long Island, NY on November 7, 2010.

Lpath, Inc. (OTCBB: LPTN), the category leader of lipidomics-based therapeutics, has been awarded two grants totaling $489,000 under the IRS Qualifying Therapeutic Discovery Project program.

Luminex Corporation (Nasdaq:LMNX) today announced financial results for the third quarter and nine months ended September 30, 2010.

Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the publication of "Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs" by Vaish et al., in the journal Nucleic Acids Research (published online November 2, 2010).

Novavax, Inc. (Nasdaq:NVAX) announced today that it has been awarded approximately $978,000 in grants under the Internal Revenue Service's Qualifying Therapeutic Discovery Project ("QTDP").

Omeros Corporation (Nasdaq:OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced its financial results for the third quarter of 2010.

OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ:OGXI) today reported unaudited financial results for the three and nine months ended September 30, 2010 and provided an update on the business, the recent financing and anticipated use of proceeds to advance the product pipeline.

OPTIMIZERx Corporation (OTCBB: OPRX) announces that on Monday, October 25th they have installed and launchedtheir SampleMD solution within the Dreyer Medical Clinics.

PharmAthene, Inc. (NYSE Amex:PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the third quarter of 2010 will be released on Thursday, November 11, 2010.

Shire plc (LSE: SHP, Nasdaq:SHPGY), the global specialty biopharmaceutical company, today presented positive new data from a Phase III clinical trial (study 039) designed to evaluate the efficacy of VPRIV® (velaglucerase alfa for injection) compared with imiglucerase in patients with type 1 Gaucher disease at the 2010 Annual American Society of Human Genetics (ASHG) in Washington, D.C.

ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that revenues for the first quarter of fiscal 2011 were $7.0 million, a 35 percent increase over revenues of $5.2 million in the first quarter of fiscal 2010.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX: VRX) today announced that the Company's Board of Directors (the "Board") has declared a one-time special dividend of US$1.00 per common share (the "Special Dividend") that shareholders of record as of the close of business on November 15, 2010 (the "Record Date") will be entitled to receive on December 22, 2010.

Also Thursday:




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter